Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

The authors would like to make the following corrections to this published paper [1].

In the original publication, there was a typographical error in the footnote for Table 1. Information in footnotes indicating previous receipt of non-study vaccines in the PPSV23 and PCV15 groups was reversed. The footnote indicated with † has been changed from “A participant in the PPSV23 sequential group had previously received an inactivated vaccine for influenza” to “A participant in the PPSV23 sequential group had previously received a vaccine for tetanus”. The footnote indicated with ‡ has been changed from “A participant in the PCV15 group had previously received a vaccine for tetanus” to “A participant in the PCV15 group had previously received an inactivated vaccine for influenza”. The corrected Table 1 appears below.

In the original publication, there were typographical errors in the population sizes for the PCV15 concomitant and PCV15 sequential groups in Table 2. The population size for the PCV15 concomitant group has been changed from “n = 211” to “n = 210”, and population size for the PCV15 sequential group has been changed from “n = 211” to “n = 208”. The corrected Table 2 appears below.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.